Thalidomide-based TNF-α inhibitors for neurodegenerative diseases

Nigel H. Greig, Tony Giordano, Xiaoxiang Zhu, Qian Sheng Yu, Tracy Ann Perry, Harold W. Holloway, Arnold Brossi, Jack T. Rogers, Kumar Sambamurti, Debomoy Lahiri

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Inflammatory processes associated with the over-production of cytokines, particularly of TNF-α, accompany numerous neurodegenerative diseases, such as Alzheimer's disease, in addition to numerous systemic conditions, exemplified by rheumatoid arthritis and erythema nodosum leprosum (ENL). TNF-α has been validated as a drug target with Remicade and Enbrel available as prescription medications. Both, however, are large macromolecules, require injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of diseases. As its clinical value in treating ENL derives from its TNF-α inhibitory activity, thalidomide was chosen for structural modification for the discovery of novel and more potent isosteric analogues with appropriate lipophilicity to insure high brain penetration. TNF-α inhibitory activity was evaluated against lipopolysacharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in cell culture, whose viability was quantified to differentiate reductions in TNF-α secretion from that associated with cellular toxicity. Specific analogues potently inhibited TNF-α secretion, compared to thalidomide. This involved a post-transcriptional mechanism, as they decreased TNF-α mRNA stability via its 3′-untranslated region (UTR), as determined by luciferase activity in stably transfected cells with and without the 3′-UTR of human TNF-α.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalActa Neurobiologiae Experimentalis
Volume64
Issue number1
StatePublished - 2004

Fingerprint

Thalidomide
Neurodegenerative Diseases
Erythema Nodosum
3' Untranslated Regions
RNA Stability
Brain
Luciferases
Pharmaceutical Preparations
Prescriptions
Blood Cells
Rheumatoid Arthritis
Alzheimer Disease
Cell Culture Techniques
Cytokines
Injections

Keywords

  • Alzheimer's disease
  • Amyloid precursor protein
  • Amyloid-β peptide
  • Erythema nodosum leprosum (ENL)
  • Lipopolysacharide (LPS)
  • Peripheral blood mononuclear cells (PBMC)
  • Rheumatoid arthritis
  • Thalidomide
  • Thalidomide analogues
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Greig, N. H., Giordano, T., Zhu, X., Yu, Q. S., Perry, T. A., Holloway, H. W., ... Lahiri, D. (2004). Thalidomide-based TNF-α inhibitors for neurodegenerative diseases. Acta Neurobiologiae Experimentalis, 64(1), 1-9.

Thalidomide-based TNF-α inhibitors for neurodegenerative diseases. / Greig, Nigel H.; Giordano, Tony; Zhu, Xiaoxiang; Yu, Qian Sheng; Perry, Tracy Ann; Holloway, Harold W.; Brossi, Arnold; Rogers, Jack T.; Sambamurti, Kumar; Lahiri, Debomoy.

In: Acta Neurobiologiae Experimentalis, Vol. 64, No. 1, 2004, p. 1-9.

Research output: Contribution to journalArticle

Greig, NH, Giordano, T, Zhu, X, Yu, QS, Perry, TA, Holloway, HW, Brossi, A, Rogers, JT, Sambamurti, K & Lahiri, D 2004, 'Thalidomide-based TNF-α inhibitors for neurodegenerative diseases', Acta Neurobiologiae Experimentalis, vol. 64, no. 1, pp. 1-9.
Greig NH, Giordano T, Zhu X, Yu QS, Perry TA, Holloway HW et al. Thalidomide-based TNF-α inhibitors for neurodegenerative diseases. Acta Neurobiologiae Experimentalis. 2004;64(1):1-9.
Greig, Nigel H. ; Giordano, Tony ; Zhu, Xiaoxiang ; Yu, Qian Sheng ; Perry, Tracy Ann ; Holloway, Harold W. ; Brossi, Arnold ; Rogers, Jack T. ; Sambamurti, Kumar ; Lahiri, Debomoy. / Thalidomide-based TNF-α inhibitors for neurodegenerative diseases. In: Acta Neurobiologiae Experimentalis. 2004 ; Vol. 64, No. 1. pp. 1-9.
@article{9d2f2b4b4bc44c6c97faf516a0e320ac,
title = "Thalidomide-based TNF-α inhibitors for neurodegenerative diseases",
abstract = "Inflammatory processes associated with the over-production of cytokines, particularly of TNF-α, accompany numerous neurodegenerative diseases, such as Alzheimer's disease, in addition to numerous systemic conditions, exemplified by rheumatoid arthritis and erythema nodosum leprosum (ENL). TNF-α has been validated as a drug target with Remicade and Enbrel available as prescription medications. Both, however, are large macromolecules, require injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of diseases. As its clinical value in treating ENL derives from its TNF-α inhibitory activity, thalidomide was chosen for structural modification for the discovery of novel and more potent isosteric analogues with appropriate lipophilicity to insure high brain penetration. TNF-α inhibitory activity was evaluated against lipopolysacharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in cell culture, whose viability was quantified to differentiate reductions in TNF-α secretion from that associated with cellular toxicity. Specific analogues potently inhibited TNF-α secretion, compared to thalidomide. This involved a post-transcriptional mechanism, as they decreased TNF-α mRNA stability via its 3′-untranslated region (UTR), as determined by luciferase activity in stably transfected cells with and without the 3′-UTR of human TNF-α.",
keywords = "Alzheimer's disease, Amyloid precursor protein, Amyloid-β peptide, Erythema nodosum leprosum (ENL), Lipopolysacharide (LPS), Peripheral blood mononuclear cells (PBMC), Rheumatoid arthritis, Thalidomide, Thalidomide analogues, TNF-α inhibitors",
author = "Greig, {Nigel H.} and Tony Giordano and Xiaoxiang Zhu and Yu, {Qian Sheng} and Perry, {Tracy Ann} and Holloway, {Harold W.} and Arnold Brossi and Rogers, {Jack T.} and Kumar Sambamurti and Debomoy Lahiri",
year = "2004",
language = "English",
volume = "64",
pages = "1--9",
journal = "Acta Neurobiologiae Experimentalis",
issn = "0065-1400",
publisher = "Nencki Institute of Experimental Biology",
number = "1",

}

TY - JOUR

T1 - Thalidomide-based TNF-α inhibitors for neurodegenerative diseases

AU - Greig, Nigel H.

AU - Giordano, Tony

AU - Zhu, Xiaoxiang

AU - Yu, Qian Sheng

AU - Perry, Tracy Ann

AU - Holloway, Harold W.

AU - Brossi, Arnold

AU - Rogers, Jack T.

AU - Sambamurti, Kumar

AU - Lahiri, Debomoy

PY - 2004

Y1 - 2004

N2 - Inflammatory processes associated with the over-production of cytokines, particularly of TNF-α, accompany numerous neurodegenerative diseases, such as Alzheimer's disease, in addition to numerous systemic conditions, exemplified by rheumatoid arthritis and erythema nodosum leprosum (ENL). TNF-α has been validated as a drug target with Remicade and Enbrel available as prescription medications. Both, however, are large macromolecules, require injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of diseases. As its clinical value in treating ENL derives from its TNF-α inhibitory activity, thalidomide was chosen for structural modification for the discovery of novel and more potent isosteric analogues with appropriate lipophilicity to insure high brain penetration. TNF-α inhibitory activity was evaluated against lipopolysacharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in cell culture, whose viability was quantified to differentiate reductions in TNF-α secretion from that associated with cellular toxicity. Specific analogues potently inhibited TNF-α secretion, compared to thalidomide. This involved a post-transcriptional mechanism, as they decreased TNF-α mRNA stability via its 3′-untranslated region (UTR), as determined by luciferase activity in stably transfected cells with and without the 3′-UTR of human TNF-α.

AB - Inflammatory processes associated with the over-production of cytokines, particularly of TNF-α, accompany numerous neurodegenerative diseases, such as Alzheimer's disease, in addition to numerous systemic conditions, exemplified by rheumatoid arthritis and erythema nodosum leprosum (ENL). TNF-α has been validated as a drug target with Remicade and Enbrel available as prescription medications. Both, however, are large macromolecules, require injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of diseases. As its clinical value in treating ENL derives from its TNF-α inhibitory activity, thalidomide was chosen for structural modification for the discovery of novel and more potent isosteric analogues with appropriate lipophilicity to insure high brain penetration. TNF-α inhibitory activity was evaluated against lipopolysacharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in cell culture, whose viability was quantified to differentiate reductions in TNF-α secretion from that associated with cellular toxicity. Specific analogues potently inhibited TNF-α secretion, compared to thalidomide. This involved a post-transcriptional mechanism, as they decreased TNF-α mRNA stability via its 3′-untranslated region (UTR), as determined by luciferase activity in stably transfected cells with and without the 3′-UTR of human TNF-α.

KW - Alzheimer's disease

KW - Amyloid precursor protein

KW - Amyloid-β peptide

KW - Erythema nodosum leprosum (ENL)

KW - Lipopolysacharide (LPS)

KW - Peripheral blood mononuclear cells (PBMC)

KW - Rheumatoid arthritis

KW - Thalidomide

KW - Thalidomide analogues

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=11144358504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144358504&partnerID=8YFLogxK

M3 - Article

C2 - 15190675

AN - SCOPUS:11144358504

VL - 64

SP - 1

EP - 9

JO - Acta Neurobiologiae Experimentalis

JF - Acta Neurobiologiae Experimentalis

SN - 0065-1400

IS - 1

ER -